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Abstract 
Introduction: Hyperglycemia first detected in pregnancy during screening test (often between 24-28 weeks) which 
does not meet the criteria for overt diabetes is called gestational diabetes mellitus (GDM). The International 
Association of Diabetes in Pregnancy Study group (IADPSG) recommended a new diagnostic criteria and protocol. 
Objective: To find out the prevalence, the need for insulin therapy, any short term maternal or fetal adverse effect of 
metformin therapy and maternal and fetal outcome of gestational diabetes mellitus in eastern part of India.  
Methods: This observational study was conducted in a tertiary care semi urban private hospital from October 2018 
to September 2019 for a period of twelve months. All women with normal fasting blood sugar at booking underwent 
oral glucose tolerance test between 24-28 weeks using 75 grams glucose drink. All GDM cases were managed by a 
multidisciplinary team. Pregnancies complicated with known type 1 or type 2 DM, preexisting hypertension and 
multiple pregnancies, were excluded from this study. Results: Out of 581 total deliveries 70 cases was GDM (12%). 
All cases received dietary modifications; metformin was needed in 62 (88.5%) and insulin required in 8 (11.5%) 
cases. 7 cases (10%) detected to have growth between 50 th and 90 th centile, interestingly 3(4.2%) cases growth 
was between 5th and 50th centile. 4 patients (5.7. %) delivered between 32 to 34 weeks and 15 (21.4%) between 34-
36 weeks. 67 (95.7%) were delivered by caesarean section. There was no perinatal loss. Conclusion: This study 
indicates that majority of the patients with GDM can be managed without insulin. Metformin use has reduced the 
need for insulin therapy. Universal screening and proper vigilance can result in optimal outcome. 
Keywords :   Gestational diabetes mellitus, diagnosis, criteria, maternal outcome, neonatal outcome. 
This is an Open Access article that uses a fund-ing model which does not charge readers or their institutions for access and distributed under the 
terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative 
(http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly credited.  
Introduction 
Hyperglycemia in pregnancy is one of the common 
medical problems, particularly in Asian countries. 
_____________________ 
*Correspondence  
Dr. Sukumar Barik 
Associate Professor, 
Department of Obstetrics and Gynecology, 
ICARE Institute of Medical Sciences and Research, 
PO- Balughata,Haldia, Purba Medinipur, West Bengal 
721645, India. 
E-mail: sukumarbarik1@gmail.com  
It is a broad term which encompasses preexisting type 
1, type 2 diabetes mellitus, overt diabetes mellitus first 
time detected in pregnancy and gestational diabetes 
mellitus (GDM). Hyperglycemia first detected in 
pregnancy during screening test (often between 24-28 
weeks) which does not meet the criteria for overt 
diabetes is called GDM [1]. Previously, diagnostic cut-
off was validated by future risk of development of type 
2 diabetes. Little attention was paid about the perinatal 
outcome of mild gestational hyperglycemia as it was 
thought to be not that significant. HAPO study [2] 
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indicated robust, continuous associations of maternal 
glucose levels below those diagnostic of diabetes with 
increased birth weight. It also suggested increased 
cord-blood serum C-peptide levels. After publication of 
HAPO study, The International Association of 
Diabetes in Pregnancy Study group recommended a 
new diagnostic criteria and protocol. This group 
suggested universal (not selective in risk group), single 
– step test (not two step) using 75 gms gram (not 100 
grams or 50 grams) glucose load. Any one elevated 
level (fasting level or one hour level after glucose drink 
or two hours level) is sufficient to make the diagnosis 
of GDM [3]. The hyperglycemia and adverse 
pregnancy outcome follow up study (HYPO FUS) 
indicated adverse impact of GDM on long-term 
maternal and infant health [4]. 
 
Aims and objectives 
To find out the prevalence, the need for insulin therapy, 
any short term maternal or fetal adverse effect of 
metformin therapy and maternal and fetal outcome of 
gestational diabetes mellitus in eastern part of India.   
 
Materials and methods 
 
This observational study was conducted in the 
department of Obstetrics and Gynecology of a tertiary 
care semi urban private hospital. The study period was 
from October 2018 to September 2019 for a period of 
twelve months. All pregnant women underwent fasting 
blood sugar test at booking visit. All women with 
normal report underwent oral glucose tolerance test 
between 24-28 weeks using 75 grams glucose drink.  
The IADPSG criteria were followed (fasting – 92 mg 
/dl, 1- hour – 180 mg/dl, 2-hour- 153 mg/dl).  All 
diagnosed cases of GDM were managed by a 
multidisciplinary team of obstetricians, diabetologists, 
dieticians and neonatologists.  
Exclusion criteria  
 Patients with known Type 1 or type 2 diabetes 
prior to the current pregnancy. 
 Multiple pregnancies.   
 Known major fetal anomaly.  
 Known hypertension before the current pregnancy. 
Ethical permission was waived as this study was 
undertaken by analyzing the routinely collected data. .  
 
Results 
 
Out of 581 total deliveries 70 cases was GDM (12%). 
All cases received dietary modifications instituted by 
specially trained dieticians. Special tailored made diet 
chart were explained to each patient.   Metformin was 
needed in 62 patients (88.5%) out of total 70 cases. 
Dose of metformin was adjusted depending on the 
follow up blood sugar reports.  Insulin was required in 
8 (11.5%) cases. Only 7 cases (10%) detected to have 
fetal growth between 50 th and 90 th centile.  
Interestingly in 3(4.2%) cases fetal growth was 
between 5th and 50th centile (Table 1). 4 cases (5.7. %) 
delivered between 32 to 34 weeks and 15 (21.4%) 
between 34-36 weeks (Table 2). 67 patients (95.7%) 
were delivered by caesarean section. There was no 
perinatal loss. Four newborn (5.7%) had transient 
trachypnoea of newborn, 3(4.2%) had hypoglycemia 
after delivery, another 3(4.2%) had hyperbilirubinemia 
needing phototherapy.  Calculation and analysis were 
done using Microsoft Excel spreadsheet. 
 
Discussion 
 
The prevalence of GDM varies significantly in 
different ethnic populations. It is well documented that 
Asians are more prone to develop GDM and 
subsequently type 2 DM after few years. According to 
IDF estimate globally, some form of hyperglycemia 
occur in one in six of the 20 million annual live births 
(16.8%). Of this large burden, 16% relate to diabetes in 
pregnancy (either preexisting type 1 or type 2 DM or 
diagnosed during pregnancy) and the remaining 84% is 
GDM. Our prevalence of 12% is very similar to the 
recently quoted data of International diabetes 
Federation data [5]. A hospital based study in south 
India adapted the IADPSG criteria and the prevalence 
of GDM was found to be 14% [6]. The controversies 
surrounding whom to screen, when to screen, how to 
screen and which criteria to follow has been clearly 
addressed in a recently published special editorial [1]. 
The IADPSG criteria are now endorsed by World 
Health Organization, and received endorsement from 
International federation of Obstetrics and Gynecology 
[7].A randomized trial published in 2005, demonstrated 
that the rate of serious perinatal complications was 
significantly lower among the infants of the treated 
group than among the infants in the routine-care group. 
They concluded that treatment of gestational diabetes 
reduces serious perinatal morbidity and may also 
improve the woman’s health-related quality of life [8]. 
Use of oral anti‐diabetic pharmacological therapies for 
treating women with GDM is still controversial. The 
Cochrane review concluded that the benefits and 
potential harms of one oral anti‐diabetic 
pharmacological therapy compared with another, or 
compared with placebo/standard care remains unclear 
and requires further research [9]. 
International Journal of Health and Clinical Research, 2020;3(4):73-76                    e-ISSN: 2590-3241, p-ISSN: 2590-325X                         
                                                             
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Barik  et al                 International Journal of Health and Clinical Research, 2020; 3(4):73-76 
www.ijhcr.com                              
                    75 
 
A meta-analysis published in 2019 concluded that 
metformin could be a safe and effective treatment for 
GDM. However, they alerted the clinicians to pay 
attention on the long-term outcomes of offspring with 
GDM patients treated with metformin. This study also 
concluded insulin therapy compared with metformin, 
had a higher increase of neonatal hypoglycemia [10]. 
Our study also demonstrated that all cases of neonatal 
hypoglycemia were seen in mothers treated with 
insulin. The MIG study from New Zealand and 
Australia in a randomized control trial assigned women 
with gestational diabetes mellitus at 20 to 33 weeks of 
gestation to open treatment with metformin, with 
insulin if required or insulin. This trial concluded in 
women with gestational diabetes mellitus, only insulin 
therapy compared with metformin alone or with 
additional insulin is not associated with better perinatal 
outcome.  Not surprisingly metformin treatment was 
preferred to insulin treatment. Compared to other oral 
hypoglycemic agents, metformin is the preferred one at 
present time for treatment of GDM [11]. 
Currently health burden and consequences of GDM in 
both the mother and the baby, as well as in subsequent 
generations have been emphasized [12, 13]. Relatively 
small sample size is one of the limitations of this study.  
 
 
 
 
 
 
 
 
 
Fig 1: Fetal Growth Chart at 33 weeks period of gestation. 
 
 
Fig 2:  Gestation at delivery (in weeks) 
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Conclusion 
 
This study indicates IADPSG criteria are robust and 
acceptable criteria for managing pregnant patients 
complicating with GDM. This study also suggests that 
majority of the cases can be managed by dietary 
modifications and metformin. A relatively small 
number of patients will need insulin therapy. Good 
control of blood sugar during pregnancy reduces the 
chance of fetal macrosomia. Metformin use during 
pregnancy did not produce any significant fetal or 
neonatal problem in short term.  
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